Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484456 | 0.78 | ACHE (0.32) | — | |
| SCHEMBL4476929 | 0.76 | SLC2A1 (0.39) | TSHR | |
| SCHEMBL4487957 | 0.76 | SLC2A1 (0.39) | — | |
| SCHEMBL4490730 | 0.75 | SLC2A1 (0.38) | MAOB | |
| SCHEMBL3397533 | 0.71 | SLC2A1 (0.42) | MAOBLMNATSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL4478743 | 0.70 | SLC2A1 (0.42) | LMNATSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL4481795 | 0.69 | ALDH1A1 (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL4483682 | 0.68 | GPR84 (0.42) | — | |
| SCHEMBL4490983 | 0.67 | ADORA2A (0.41) | LMNATSHRSMN1; SMN2PTGS2 | |
| SCHEMBL4490544 | 0.67 | BRD4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246329-A1 | 4(1H)-pyridinone derivatives and their use as antimalaria agents | Glaxo Group Limited (GB) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010081904-A1 | 4 ( 1H) -PYRIDINONE DERIVATIVES AND THEIR USE AS ANTIMALARIA AGENTS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |